Parke Davis: Uncertainty affects valuation - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Parke Davis: Uncertainty affects valuation

Dec 20, 2000

That international mergers create uncertainty is a given. This holds good for the management, the employees as well as the shareholders. A recent example is that of Parke Davis. The company till recently was an affiliate of the $ 9 bn Warner Lambert which held 40% in its Indian arm. The takeover of Warner Lambert by Pfizer and the presence of a two parallel 100% subsidiaries in India has led to a uncertainty about the prospects of Parke Davis and this has affected the valuation of the company.

International media reports have mentioned that Pfizer has cleared out several layers of Warner Lambert management leaving hardly any senior positions for the Warner Lambert staff as it consolidates its acquisition. What way the merger pans out in India remains to be seen.

In India, Parke Davis has a presence in gynaec care, cardiac care, pediatric care and neuro care. It’s cough syrup Benadryl is the third largest brand in the Rs 4.8 bn cough and colds market after Corex (Pfizer) and Phensedyl (Rhone Poulenc). Its over–the–counter products include Waterbury’s Compound (a health tonic), Gelusil (an antacid), Neko (a bath soap) and Listerine (an oral hygiene product). These contributed nearly 20% to the company’s turnover of Rs 1,793 m last year.

Over the past two years Parke Davis also launched products such as Walcillin (an amoxycillin based antibiotic), Atpark (cardiovasdcular) and Calcal (a calcium supplement). Though these products are based on much older molecules, they have done well and account for almost 12% of the company’s sales.

Last year the company sold its Saki Naka plant (in Mumbai) for Rs 493 m. However, the company has still not received the full payment for the same. (The workers of the plant were paid off via a Voluntary Retirement Scheme.)

Also, the company does not have a reputation for being minority shareholder friendly. A prominent example was the transfer, in the past, of cough lozenges ‘Halls’ and ‘Chiclets’ to the 100% subsidiary of its parent Warner Lambert India.

Coming to the financials, the company reported a 15% growth in its net profit in the first half of the current year. The write off of VRS expenditure was completed last year and this has led to a higher tax payment in the current year. At the current price of Rs 267, the stock price implies an earning multiple of 17 times its annualised earnings of FY01. This is relatively lower than the earnings multiples enjoyed by its peers. Keeping in mind the uncertainty regarding the merger and the way Pfizer has gone about the management changes, we don’t expect a favourable ratio for Parke Davis.


Equitymaster requests your view! Post a comment on "Parke Davis: Uncertainty affects valuation". Click here!

  

More Views on News

ADVANCED ENZYME TECHNOLOGIES Share Price Up by 10%; BSE HEALTHCARE Index Up 0.4% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

ADVANCED ENZYME TECHNOLOGIES share price is trading up by 10% and its current market price is Rs 302. The BSE HEALTHCARE is up by 0.4%. The top gainers in the BSE HEALTHCARE Index is ADVANCED ENZYME TECHNOLOGIES (up 10.0%). The top losers are CADILA HEALTHCARE (down 0.1%) and APOLLO HOSPITALS (down 0.2%).

GRANULES INDIA Share Price Up by 6%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

GRANULES INDIA share price is trading up by 6% and its current market price is Rs 395. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index is GRANULES INDIA (up 5.8%). The top losers are ABBOTT INDIA (down 0.2%) and ALKEM LABORATORIES (down 0.8%).

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 25, 2020 12:01 PM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS